At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 634 enrolled
Drug / intervention
Ferumoxytoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia
In Brief
A Phase 3 clinical trial evaluating Ferumoxytol for Iron Deficiency Anemia. Completed, enrolled 634 participants across 140 sites in 6 countries.
Detailed Summary
To evaluate the safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia (IDA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Deficiency Anemia
CountriesCanada, Hungary, India, Latvia, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJul 2010
Primary CompletionSep 2012
Study CompletionApr 2013
TodayJul 2026
First PostedMay 3, 2010
Enrollment StartJul 27, 2010
Primary CompletionSep 24, 2012
Study CompletionApr 23, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.2 years ago
Interventions
Ferumoxytoldrug
IV Ferumoxytol